Actemra
E238180
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Actemra canonical | 2 |
| tocilizumab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2138514 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Actemra Context triple: [Roche, product, Actemra]
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Actemra Target entity description: Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
immunosuppressive agent ⓘ interleukin-6 receptor inhibitor ⓘ prescription drug ⓘ |
| affects | IL-6–mediated signaling pathways ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToClass |
disease-modifying antirheumatic drugs
ⓘ
monoclonal antibodies ⓘ |
| canBeUsedAs | monotherapy for rheumatoid arthritis ⓘ |
| contraindicatedIn | patients with active serious infections ⓘ |
| developedBy |
Chugai Pharmaceutical
ⓘ
Roche ⓘ
surface form:
Hoffmann-La Roche
|
| hasActiveIngredient |
Actemra
self-linksurface differs
ⓘ
surface form:
tocilizumab
|
| hasATCCode | L04AC07 ⓘ |
| hasDosageForm |
solution for infusion
ⓘ
solution for subcutaneous injection ⓘ |
| hasGenericName | tocilizumab ⓘ |
| indicatedFor | moderate to severe rheumatoid arthritis ⓘ |
| isBrandNameOf | tocilizumab ⓘ |
| mayCause |
elevated liver enzymes
ⓘ
gastrointestinal perforation ⓘ increased risk of infections ⓘ neutropenia ⓘ thrombocytopenia ⓘ |
| mechanismOfAction | IL-6 receptor blockade ⓘ |
| oftenUsedWith | methotrexate ⓘ |
| reduces |
C-reactive protein levels
ⓘ
acute phase reactants ⓘ joint inflammation ⓘ joint pain ⓘ |
| regulates | inflammatory response ⓘ |
| requiresMonitoring |
complete blood count
ⓘ
lipid profile ⓘ liver function tests ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targets | interleukin-6 receptor ⓘ |
| treats |
COVID-19–related cytokine storm
ⓘ
cytokine release syndrome ⓘ giant cell arteritis ⓘ polyarticular juvenile idiopathic arthritis ⓘ rheumatoid arthritis ⓘ systemic juvenile idiopathic arthritis ⓘ |
| usedIn |
adult patients
ⓘ
pediatric patients with certain indications ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Actemra Description of subject: Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
tocilizumab